For over 20 years, BIG has been conducting global breast cancer trials and research programmes.
Many are considered to be landmark, introducing particularly innovative designs, contributing to significant breakthroughs, or paving the way towards more personalised treatment of breast cancer.
The international randomised SOFT & TEXT clinical trials offer a new post-operative treatment option for young women with hormone-sensitive early breast cancer.
The APHINITY trial found that adjuvant pertuzumab in combination with trastuzumab and chemotherapy in patients significantly improved the rates of invasive-disease-free survival among patients with HER2-positive, operable breast cancer when it was added to trastuzumab and chemotherapy.
The MINDACT trial found that 46% of patients identified as high-risk for cancer recurrence based on traditional factors were identified as low-risk when adding the MammaPrint® test. It represents a large academic effort towards de-escalating therapies.
Finding a cure is one of the biggest challenges faced by researchers from around the world. Breast cancer affects women and men of all ages. This is why prevention is crucial. When breast cancer is diagnosed, the impact on a patient’s life and loved ones is devastating and causes intense stress. Appropriate psychological and moral support is needed and can really make a big difference.
It is crucial to identify the most appropriate and personalised therapies to increase the chances of recovery and cure. BIG fosters collaboration among the world’s leading experts in breast cancer and advances research. This is essential to give hope to everyone concerned.
HRM the Queen of the Belgians, Honorary President of the Breast International Group
There are many areas of research that hold great promise for patients but have no particular interest for commercial partners.
That is why BIG develops and runs academic studies that hold tremendous potential for patients and promise long-term gains for society, in all regions of the world. Thanks to our global network of breast cancer experts, we can run these trials more efficiently.
– Martine Piccart, Co-founder and President of BIG against breast cancer
94,4% of all funds received by BIG in 2020, including funds raised by BIG against breast cancer, went directly to BIG's research.
By attending a BIG event, you're not only creating memories, you're also supporting BIG's academic studies.
Run the 20 KM of Brussels with BIG and support breast cancer research! Registration is now open to run or...
Learn moreAt this year’s St. Gallen Breast Cancer Congress (SGBCC, 15-18...
Results of the final analysis of the NeoALTTO study have...
The results of the combined SOFT-TEXT analysis after 13 years...
Breast international group (BIG) – aisbl
Rue de bretagne 20,
1200 Brussels, Belgium
VAT BE 0468 176 240
IBAN BE08 0689 0916 0213
The Breast International Group is proud to adhere
to the Code of Ethics of the VEF-AERF
© 2022 All rights reserved
Breast international group (BIG) - aisbl
